Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid intestinal insulin-stimulating factor, which is mainly secreted by L cells in the distal ileum and colon. It has various physiological functions, such as promoting insulin secretion and synthesis, stimulating β-cell proliferation, inducing islet reg...
Saved in:
Main Authors: | Xu He, Wei Zhao, PeiHang Li, YinJiang Zhang, GuoHua Li, HongYu Su, BiNan Lu, ZongRan Pang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1483792/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01) -
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
by: Tohada M. AL-Noshokaty, et al.
Published: (2025-06-01) -
Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01) -
GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01) -
Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two‐Centre Open, Single‐Arm Trial
by: Chuanfeng Liu, et al.
Published: (2025-01-01)